Key Metrics 
Check Before You Invest 
10 Yrs X-Ray 
Valuation 
Analyst Note 
Qtr. Results 
Financials 
News 
About
Global Health Ltd (MEDANTA)
Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 543654 NSE: MEDANTA Hospital & Healthcare Services | Small Cap | Global Health Share Price
₹1,433.80 -61.50 (-4.11%)
As on 28-Sep'26 16:59
Global Health Ltd (MEDANTA)
Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 543654 NSE: MEDANTA Hospital & Healthcare Services | Small Cap | Global Health Share Price
₹1,433.80 -61.50 (-4.11%)
As on 28-Sep'26 16:59
Key Metrics
Valuation Multiples
Market Cap
₹38,551 Cr.
Current Price
₹1,433.8
52-Week Low / High
₹955 / 1,542
TTM EPS
₹20.7
TTM Sales
₹4,683 Cr.
Book Value per Share
₹152.9
P/E Ratio
69.31
In line with its 5-year historical median
Industry PE
98.6
Price to Book (P/B)
9.38
Higher than its 5-year historical median
Price to Sales (P/S)
8.23
Lower than its 5-year historical median
EV/EBITDA
35.26
Lower than its 5-year historical median
Dividend Yield
0.03%
Profitability Efficiency
Return on Equity (ROE)
15.12%
Outperforms industry median
Return on Capital Employed (ROCE)
19.38%
Outperforms industry median
Return on Assets (ROA)
10.43%
Operating Profit Margin
21%
Net Profit Margin
12.56%
Gross Profit Margin
21.3%
Growth Momentum
1-yr vs 3-yr growth
1-yr vs 3-yr growth
Sales Growth (1 Year)
Slowing versus 3-year growth rate
15.77%
Operating Profit Growth (1 Year)
Slowing versus 3-year growth rate
7.41%
Net Profit Growth (1 Year)
Slowing versus 3-year growth rate
15.11%
Asset Quality
Promoter Holding
33.00%
Pledged shares (%) of Promoter's holding (%)
0.00%
Reserves
₹4,058 Cr.
Equity
₹53.8 Cr.
Face Value
₹2
All Time Low / High
₹391.05 / 1542.00
Check Before You Invest
Quality
Somewhat GoodValuation
Somewhat OvervaluedCheck Valuation charts
Price Trend
Semi Strong
Is Global Health Ltd a good quality company?
Global Health Ltd is a average quality company, based on a somewhat consistent multi-year financial track record.
This assessment is based on company’s performance on Revenue growth, ROCE, Equity and Assets, key margin ratios, cash conversion cycle, and debt to cash flow from operations and how it compares with its long term averages.
We have analysed the performance of the company on the following:
-
How has it performed on generating Profits?
By checking its Revenue growth, Gross, Operating and Net Margins compared to its last 5-year median.
-
How efficiently has it utilized Capital?
By checking its ROCE, ROA, ROE and its Cash Conversion Cycle.
-
How is it managing its Debt?
By checking its Debt to Equity and Cash Flow from Operations.
How does Global Health Ltd performance compare with that of its Peers?
Revenue growth of Global Health Ltd vs industry peers?
Global Health Ltd revenue CAGR is 24.97%, compared to the industry median CAGR of 0%, indicating faster growth and gaining its market share.
Promoter shareholding and pledge status of Global Health Ltd?
Promoters hold 33.00% of the Global Health Ltd, with 0.00% of their stake pledged, indicating no pledge risk.
Stock return of Global Health Ltd over the last decade?
Over the last 3 year(s), the stock has delivered a CAGR of 26.43% based on the current price.
10 Year X-Ray :
Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year endData adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
What is a Financial Track Record? How to read this chart in order to understand the data present here?
Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Global Health Ltd has performed well in some of the past ten years indicating its past ten year financial track record is somewhat good
Value Creation ⓘ
| Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % ⓘ | 8.9% | 6.8% | 8.3% | 11.3% | 7.7% | 19.5% | 17.2% | 24.3% | 19.3% | 17.3% | - |
| Value Creation Index ⓘ | -0.2 | -0.4 | -0.3 | 0 | -0.3 | 0.4 | 0.3 | 1.2 | 0.7 | 0.5 | - |
Growth Parameters ⓘ |
|||||||||||
| Sales ⓘ | 1,277 | 1,343 | 1,441 | 1,472 | 1,227 | 1,765 | 1,974 | 2,280 | 3,204 | 3,709 | 3,906 |
| Sales YoY Gr. | - | 5.2% | 7.3% | 2.2% | -16.6% | 43.8% | 11.8% | 15.5% | 40.5% | 15.8% | - |
| Adj EPS ⓘ | 2.3 | 1.6 | 2.6 | 4.1 | 2.3 | 8.6 | 9.9 | 13.4 | 18.5 | 18.5 | 17.9 |
| YoY Gr. | - | -32.3% | 69.7% | 57.4% | -44.7% | 276.9% | 14.5% | 35.8% | 37.6% | 0% | - |
| BVPS (₹) ⓘ | 44.4 | 46 | 49.9 | 54.4 | 57.2 | 68.5 | 92.6 | 105.9 | 130.2 | 148.7 | 154.1 |
| Adj Net Profit ⓘ | 55.5 | 37.5 | 64.7 | 102 | 56.8 | 219 | 265 | 360 | 496 | 496 | 482 |
| Cash Flow from Ops. ⓘ | 124 | 80.1 | 152 | 193 | 201 | 235 | 431 | 341 | 528 | 573 | - |
| Debt/CF from Ops. ⓘ | 1.5 | 2.1 | 0.9 | 0.1 | 0.1 | 0.5 | 0.2 | 0.2 | 0.3 | 0.8 | - |
CAGR ⓘ
| 9 Years | 5 Years | 3 Years | 1 Years | |||||
|---|---|---|---|---|---|---|---|---|
| Sales ⓘ | 12.6% | 24.8% | 23.4% | 15.8% | ||||
| Adj EPS ⓘ | 26.1% | 51.8% | 23.2% | 0% | ||||
| BVPSⓘ | 14.4% | 21.1% | 17.1% | 14.2% | ||||
| Share Price | - | - | 26.1% | 8.7% | ||||
Key Financial Parameters ⓘ
| Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity % ⓘ | 5 | 3.2 | 5.1 | 7.5 | 3.9 | 13.6 | 12.5 | 13.5 | 15.2 | 13.2 | 11.8 |
| Op. Profit Mgn % ⓘ | 10 | 9.7 | 10.1 | 14.9 | 14.1 | 21.6 | 21.5 | 22.1 | 23.3 | 20.4 | 20.2 |
| Net Profit Mgn % ⓘ | 4.3 | 2.8 | 4.5 | 6.9 | 4.6 | 12.4 | 13.4 | 15.8 | 15.5 | 13.4 | 12.3 |
| Debt to Equity ⓘ | 0.2 | 0.2 | 0.1 | 0 | 0 | 0.1 | 0 | 0 | 0 | 0.1 | - |
| Working Cap Days ⓘ | 54 | 65 | 73 | 80 | 154 | 158 | 167 | 193 | 168 | 122 | 77 |
| Cash Conv. Cycle ⓘ | -3 | 5 | 9 | 5 | 10 | 9 | 8 | 4 | 8 | 13 | 50 |
Valuation of Global Health - Consolidated
Analyst's Notes
No data found!
Management X-Ray
Shareholding Pattern
Promoter's Holding & Share Pledging
| Pledged * | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
* Pledged shares as % of Promoter's holding (%)
Financials
| PARTICULARS | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,277 | 1,343 | 1,441 | 1,500 | 1,447 | 2,167 | 2,710 | 3,275 | 3,692 | 4,410 |
| Operating Expenses ⓘ + | 1,155 | 1,218 | 1,299 | 1,309 | 1,250 | 1,709 | 2,074 | 2,466 | 2,832 | 3,486 |
| Operating Profit ⓘ | 122 | 125 | 142 | 192 | 197 | 458 | 636 | 809 | 860 | 924 |
| Operating Profit Margin (%) | 9.6% | 9.3% | 9.9% | 12.8% | 13.6% | 21.1% | 23.5% | 24.7% | 23.3% | 21.0% |
| Other Income ⓘ + | 67 | 49 | 65 | 44 | 31 | 39 | 49 | 75 | 105 | 104 |
| Interest ⓘ | 23 | 28 | 21 | 57 | 73 | 86 | 86 | 84 | 74 | 90 |
| Depreciation ⓘ | 81 | 86 | 91 | 115 | 123 | 130 | 150 | 173 | 194 | 223 |
| Profit Before Tax ⓘ | 85 | 60 | 95 | 64 | 32 | 281 | 449 | 627 | 647 | 715 |
| Tax ⓘ | 35 | 27 | 34 | 28 | 4 | 84 | 123 | 149 | 166 | 161 |
| Profit After Tax | 51 | 33 | 61 | 36 | 29 | 196 | 326 | 478 | 481 | 554 |
| PAT Margin (%) | 4.0% | 2.5% | 4.2% | 2.4% | 2.0% | 9.1% | 12.0% | 14.6% | 13.0% | 12.6% |
| Adjusted EPS (₹) | 2.1 | 1.4 | 2.5 | 1.5 | 1.2 | 7.8 | 12.2 | 17.8 | 17.9 | 20.7 |
| Dividend Payout Ratio (%) | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 2.80% | 2.40% |
| PARTICULARS | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
Equity and Liabilities | |||||||||||
| Shareholders Fund + | 1,097 | 1,143 | 1,251 | 1,301 | 1,350 | 1,610 | 2,423 | 2,901 | 3,386 | 3,945 | |
| Debt + | 162 | 403 | 589 | 606 | 578 | 768 | 737 | 283 | 264 | 601 | |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -0 | 1 | 23 | |
| Trade Payables | 104 | 106 | 126 | 131 | 132 | 134 | 195 | 187 | 195 | 242 | |
| Others Liabilities ⓘ | 289 | 332 | 292 | 679 | 1,027 | 1,109 | 735 | 871 | 887 | 1,078 | |
| Total Liabilities ⓘ | 1,653 | 1,984 | 2,259 | 2,716 | 3,087 | 3,622 | 4,090 | 4,243 | 4,733 | 5,889 | |
Fixed Assets | |||||||||||
| Net Fixed Assets ⓘ + | 972 | 1,089 | 1,030 | 1,703 | 1,616 | 1,776 | 2,050 | 2,236 | 2,514 | 3,795 | |
| CWIP ⓘ | 10 | 317 | 656 | 382 | 464 | 439 | 327 | 388 | 533 | 132 | |
| Investments ⓘ | 5 | 5 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 3 | |
| Inventories | 21 | 23 | 23 | 39 | 40 | 53 | 60 | 67 | 67 | 79 | |
| Trade Receivables | 107 | 152 | 164 | 149 | 134 | 180 | 194 | 215 | 292 | 411 | |
| Cash Equivalents | 470 | 260 | 266 | 250 | 289 | 512 | 1,278 | 1,175 | 1,122 | 1,130 | |
| Others Assets ⓘ | 67 | 139 | 120 | 193 | 545 | 661 | 180 | 162 | 202 | 339 | |
| Total Assets ⓘ | 1,653 | 1,984 | 2,259 | 2,716 | 3,087 | 3,622 | 4,090 | 4,243 | 4,733 | 5,889 | |
| PARTICULARS | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash Flow From Operating Activity ⓘ + | 115 | 63 | 150 | 175 | 242 | 311 | 645 | 612 | 624 | 714 |
| Cash Flow From Investing Activity ⓘ + | -107 | -69 | -243 | -87 | -239 | -421 | -342 | -441 | -721 | -1,089 |
| Cash Flow From Financing Activity ⓘ + | -6 | 9 | 113 | -1 | -81 | 160 | 346 | -514 | -97 | 272 |
| Net Cash Flow ⓘ | 2 | 3 | 19 | 87 | -78 | 50 | 648 | -343 | -194 | -103 |
| PARTICULARS | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 |
|---|---|---|---|---|---|---|---|---|---|---|
| Ratios | ||||||||||
| ROE (%) | 4.87 | 3.03 | 5.24 | 2.92 | 2.23 | 13.4 | 16.17 | 17.96 | 15.31 | 15.12 |
| ROCE (%) | 8.63 | 5.94 | 6.55 | 6.2 | 5.26 | 16.38 | 18.71 | 21.56 | 20.5 | 19.38 |
| Asset Turnover Ratio | 0.81 | 0.74 | 0.68 | 0.6 | 0.5 | 0.65 | 0.7 | 0.79 | 0.82 | 0.83 |
| PAT to CFO Conversion(x) | 2.25 | 1.91 | 2.46 | 4.86 | 8.34 | 1.59 | 1.98 | 1.28 | 1.3 | 1.29 |
| Working Capital Days | ||||||||||
| Receivable Days | 26 | 35.10 | 40 | 38.10 | 35.70 | 26.40 | 25.20 | 22.80 | 25.10 | 29.10 |
| Inventory Days | 7 | 6 | 5.80 | 7.50 | 9.90 | 7.80 | 7.70 | 7.10 | 6.60 | 6.10 |
| Payable Days | 125.80 | 122.60 | 130.70 | 147.10 | 139.30 | 91 | 97.60 | 91.70 | 79.20 | 80 |
Top 5 Mutual Funds Holding
Last Visited Stocks
Announcements
Global Health Ltd FAQs
The current trading price of Global Health on 28-Sep-2026 16:59 is ₹1,433.8.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 27-Sep-2026 the market cap of Global Health stood at ₹38,551.3 Cr
The latest P/E ratio of Global Health as of 27-Sep-2026 is 80.06.
The latest P/B ratio of Global Health as of 27-Sep-2026 is 9.31.
The 52-week high of Global Health is ₹1,542 and the 52-week low is ₹955.2.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Global Health is ₹3,906 ( Cr.) .
Past 10 year's financial track record analysis by Moneyworks4me indicates that Global Health Ltd is a average quality company.
The key valuation ratios of Global Health Ltd's currently when compared to its past seem to suggest it is in the Somewhat overvalued zone.
The Price Trend analysis by MoneyWorks4Me indicates it is Semi Strong which suggest that the price of Global Health Ltd is likely to Rise-somewhat in the short term. However, please check the rating on Quality and Valuation before investing.
About Global Health Ltd
Global Health, operating under the Medanta brand, is one of India’s largest private providers of multi-speciality tertiary and quaternary care. The company serves the peoples through its flagship Medicity campus in Gurugram, along with a growing network of hospitals located in Indore, Ranchi, Lucknow, and Patna. The company delivers a comprehensive range of services across several medical specialties, including cardiac sciences, neurosciences, oncology, orthopaedics, liver transplants, and kidney and urology care. The company has team of doctors, supported by a 24/7 command centre and advanced operations control systems, ensures the delivery of high-quality, responsive, and coordinated patient care.
Medanta was founded by Dr Naresh Trehan, a worldrenowned cardiovascular and cardiothoracic surgeon. Dr Trehan’s vision shaped the Medanta model of care, emphasising clinical excellence and smooth coordination across super-specialities to provide advanced, specialised treatment. Medanta is deeply committed to compassionate care that places patient needs at the centre and is driven by a relentless pursuit of clinical excellence.
The company was incorporated as ‘Global Health Private Limited’ on August 13, 2004 at New Delhi, India as a private limited company under the Companies Act, 1956 pursuant to a certificate of incorporation by the Registrar of Companies, Delhi and Haryana at Delhi (RoC). The company was then converted into a public limited company under the Companies Act, 2013, pursuant to a special resolution passed by its Shareholders at the EGM held on July 31, 2021 and consequently, the name of the Company was changed to ‘Global Health Limited’ and a fresh certificate of incorporation dated August 11, 2021 was issued by the RoC.
Business area of the company
The company is engaged in the business of providing healthcare services. The company delivers a comprehensive range of services across several medical specialties, including cardiac sciences, neurosciences, oncology, orthopaedics, liver transplants, and kidney and urology care.
Segments of business operations
- Medanta Hospitals: Medanta operates major hospitals located in Gurugram, Lucknow, Patna, Indore, and Ranchi, serving key regions across northern and eastern India.
- Medanta Labs: Medanta launched its retail diagnostics business in January 2023 with the objective of enhancing accessibility and convenience by bringing high-quality diagnostic services closer to patients’ homes.
- Medanta Pharmacy: Medanta’s pharmacy services encompass both inhospital outpatient pharmacies and standalone retail outlets, ensuring convenient and reliable access to medications for patients throughout their treatment journey.
- Medanta Clinics: Medanta has established a growing network of multi-specialty clinics across some cities, designed to bring specialised care closer to patients’ homes.
- Medanta Homecare: Medanta Homecare delivers personalised medical support to patients requiring medium to high-acuity care in the comfort of their own homes.
Key awards, accreditations, certifications and recognitions
Accreditations
- 2011: 1st National Accreditation Board for Hospitals and Healthcare Providers (“NABH”) accreditation for the hospital at Gurugram
- 2011: 1st National Accreditation Board for Testing and Calibration Laboratories accreditation for the hospital at Gurugram.
- 2013: 1st Joint Commission International (JCI) accreditation for the hospital at Gurugram
- 2014: 1st NABH (blood bank) accreditation for the hospital at Gurugram.
- 2016: 1st NABH accreditation for the hospital at Indore.
- 2018: 1st NABH accreditation for the hospital at Ranchi.
- 2020: 1st NABH accreditation for the Medanta Institutional Ethics Committee at the hospital at Gurugram.
- 2022: 1st NABH accreditation for the hospital at Lucknow.
Awards
- 2020: Hospital at Gurugram ranked as the best private hospital in India by Newsweek.
- 2021: Hospital at Gurugram featured in the top 200 global hospitals by Newsweek.
- 2021: Hospital at Gurugram ranked as the best private hospital in India by Newsweek.
- 2021: Hospital at Gurugram featured in the list of world’s best specialised hospitals for cardiology by Newsweek.
- 2021: Hospital at Gurugram awarded ‘Best Multi-Speciality Hospital – National’ at ‘The Economic Times Healthcare Awards, 2021’.
- 2021: Hospital at Gurugram ranked as the best multi-specialty private hospital in North India by The Week.
- 2021: Hospital at Gurugram was ranked first for emergency, neurology, gynaecology, and ranked second for cardiology, gastroenterology, nephrology, oncology and urology by The Times of India’s Critical Care Study 2021.
- 2022: Hospital at Gurguram featured in the list of world’s best specialised hospitals for cardiology and neurology by Newsweek.
- 2022: Hospital at Gurugram featured in the top 250 global hospitals by Newsweek.
- 2022: Hospital at Gurugram ranked as the best private hospital in India by Newsweek.
- 2022: Hospital at Gurugram ranked as the best multi-speciality private hospital in North India and the second best private hospital in India as per Best All India Multi Speciality Hospital Ranking 2022 by Outlook and NEB Research.
- 2022: Medanta Gurugram- Among Top Hospitals in 9 Categories- Times Health Survey
- 2023: Medanta Gurugram-Best Private Hospital in India for 4 Years in a Row- Newsweek
- 2024: Medanta Gurugram-Best Private Hospital in India for 5 Years in a Row- Newsweek
- 2025: Medanta Gurugram - Best Healthcare Brands of 2025 - The Economic Times
- 2025: Medanta Gurugram - Best Private Hospital in India for 6 Years in a Row- Newsweek
- 2026: Medanta Gurugram – No. 1 Hospital in India Among the World's Best Hospitals 7 Years in a Row - Newsweek
Major Events:
- 2009: Establishment and commencement of operations of Medanta – the Medicity Hospital at Gurugram.
- 2010: Leased premises for clinic at the Indira Gandhi International Airport, New Delhi.
- 2010: Leased premises for clinic at Defence Colony, New Delhi.
- 2013: Anant Investments (i.e., Investor Selling Shareholder) invested in Company.
- 2013: Leased premises for clinic at DLF Cybercity.
- 2014: Entered into a 27-year lease for hospital at Indore.
- 2015: Dunearn Investments (Mauritius) Pte Ltd invested in Company.
- 2015: Entered into a 15-year lease for hospital at Ranchi.
- 2015: GHPPL entered into a 33-year concession agreement with Governor of Bihar for the development, operation and maintenance of a proposed hospital on public-private partnership at Patna.
- 2016: Entered into a 90-year lease for a proposed hospital at Noida.
- 2019: Commencement of operations of new hospital at Lucknow by MHPL.
- 2020: Gurugram hospital outpatient department pharmacy taken in-house.
- 2020: Launch of outpatient department at hospital at Patna by GHPPL.
- 2021: Lucknow hospital outpatient department pharmacy taken in-house.
- 2021: Indore hospital outpatient department pharmacy taken in-house.
- 2021: Ranchi hospital outpatient department pharmacy taken in-house.
- 2021: Launch of outpatient department pharmacy at south Delhi clinic.
- 2022: Patna hospital’s inpatient department facility commenced operations.
- 2022: Launch of Patna hospital outpatient department pharmacy.
- 2022: Leased premises for clinic at Subhash Chowk.
- 2022: Global Health Ltd IPO listed on BSE and NSE on November 16
- 2025: Medanta Hospital Noida - 550 beds and over 130 ICU beds
- 2025: Medanta Hospital Ranchi - 110 Beds and 25 ICU beds
You have 43 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now
